The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMED.L Regulatory News (MED)

  • There is currently no data for MED

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FDA filing submitted for second ScanNavAI software

18 Sep 2020 07:00

RNS Number : 3634Z
Intelligent Ultrasound Group PLC
18 September 2020
 

Intelligent Ultrasound Group plc

("Intelligent Ultrasound" or the "Company")

 

FDA filing submitted for second ScanNav AI software

 

Intelligent Ultrasound (AIM: MED), the artificial intelligence (AI) based ultrasound software and simulation company, announces that it has submitted its De Novo filing to the US Food & Drug Administration ('FDA') for its ScanNav AnatomyGuide Peripheral Nerve Block (PNB) artificial intelligence-based software.

 

Following on from the CE regulatory submission in July this year, and subject to CE and FDA approval, the Company is aiming for initial revenues in the second half of 2021.

 

The ScanNav AnatomyGuide PNB AI software will, automatically and in real-time, identify and highlight structures such as nerves and arteries on the live ultrasound scan image that are important to be identified during PNB needling procedures.

 

ScanNav AnatomyGuide PNB Trainer, a classroom-based version of the product, that does not require regulatory approval and aims to provide pre-clinical teaching to clinicians, is expected to be available for sale to hospital training departments during Q1 2021.

 

Both products will initially be sold through the Group's existing direct sales channels in the UK and North American markets.

 

Nicholas Sleep, CTO of Intelligent Ultrasound, said:

 

"This is an important milestone in the process of bringing our ScanNav AnatomyGuide AI software to market. Although we continue to discuss with manufacturers the option of integrating our software into their future ultrasound machines, the FDA and CE submissions are a key step in enabling us to bring our own ultrasound AI products to market in 2021."

 

 

For further information, please contact:

 

Intelligent Ultrasound Group plc 

www. intelligentultrasound.com

Stuart Gall, CEO Helen Jones, CFO

Tel: +44 (0)29 2075 6534 

Cenkos Securities - Nominated Advisor and Broker

Tel: +44 (0)20 7397 8900 

Giles Balleny / Cameron MacRitchie (Corporate Finance)

Michael Johnson / Julian Morse (Sales) 

Walbrook PR 

Tel: +44 (0)20 7933 8780 or intelligentultrasound@walbrookpr.com 

Anna Dunphy / Paul McManus 

Mob: +44 (0)7876 741 001 / Mob: +44 (0)7980 541 893

 

About Intelligent Ultrasound Group

Intelligent Ultrasound (AIM: MED) develops artificial intelligence-based clinical image analysis software tools for the diagnostic medical ultrasound market and hi-fidelity virtual reality simulators for the ultrasound training market.

Based in Cardiff in the UK and Atlanta in the US, the Group operates two divisions:

 

Clinical AI Division

Focusses on developing deep learning-based algorithms to make ultrasound machines smarter and more accessible. Products in development include ScanNav which uses machine-learning based algorithms to automatically identify and grade ultrasound images to provide scan assessment and audit of protocol-based ultrasound scanning; and  ScanNav AnatomyGuide, which aims to simplify ultrasound-guided needling by providing the user with real-time AI-based anatomy highlighting software for a range of medical procedures. 

 

Simulation Division 

Focusses on hi-fidelity ultrasound education and training through simulation. Its three main products are the ScanTrainer OBGYN training simulator, the HeartWorks echocardiography training simulator and the BodyWorks Eve Point of Care and Emergency Medicine training simulator. To date over 900 simulators have been sold to over 500 medical institutions around the world.

 

www.intelligentultrasound.com

 

AI products in development may require US FDA or other regulatory approval, as such this material should be considered informational only and does not constitute an offer to sell or infer claims or benefits.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCLRMLTMTMBBAM
Date   Source Headline
17th Dec 20207:00 amRNSChange of ticker
2nd Dec 20207:00 amRNSChange of auditor
30th Oct 20207:00 amRNSVoluson SWIFT receives FDA clearance
30th Sep 20207:00 amRNSGE Healthcare launches new ultrasound AI software
21st Sep 20207:00 amRNSChange of Registered Office
18th Sep 20207:00 amRNSFDA filing submitted for second ScanNavAI software
16th Sep 20207:00 amRNSFormation of Nomination Committee
6th Aug 20207:00 amRNSHalf-year Report
3rd Aug 20207:00 amRNSNotice of Results
13th Jul 20207:00 amRNSTrading Update
18th Jun 202011:30 amRNSResult of AGM
18th May 20207:00 amRNSNotice of AGM and publication of Annual Report
7th May 20205:29 pmRNSHolding(s) in Company
7th May 202011:03 amRNSHolding(s) in Company
6th May 20209:36 amRNSDirector dealings
4th May 202011:27 amRNSResult of General Meeting & Total Voting Rights
24th Apr 20202:57 pmRNSGrant of Options
22nd Apr 20207:00 amRNSBodyWorks COVID-19 Ultrasound Simulator case study
17th Apr 20203:22 pmRNSPlacing to raise £5.2m and Notice of GM
3rd Apr 20207:00 amRNSNHS Nightingale ExCel Hospital
26th Mar 20207:00 amRNSFinal Results
25th Mar 20207:00 amRNSCOVID-19 update; COVID-19 training module launch
4th Mar 20207:00 amRNSISO13485 certification for medical devices
4th Mar 20207:00 amRNSDirector/PDMR Shareholding
28th Feb 20207:00 amRNSNotice of Results
6th Feb 20207:00 amRNSGrowth & Innovation Forum 2020
29th Jan 20207:00 amRNSMinisterial visit to Intelligent Ultrasound HQ
8th Jan 20207:00 amRNSTrading Update
26th Nov 20197:00 amRNSDirectorate Changes
25th Nov 20197:00 amRNSContingent Liability Update
17th Oct 20191:00 pmRNSAgreement with FUJIFILM SonoSite, Inc.
23rd Sep 20197:00 amRNSUltrasound AI database exceeds four million images
4th Sep 20197:00 amRNSClarification of change of holding
2nd Sep 201911:48 amRNSHolding(s) in Company
30th Aug 20196:17 pmRNSHolding(s) in Company
28th Aug 20195:16 pmRNSHolding(s) in Company
28th Aug 20199:12 amRNSDirector/PDMR Shareholding
27th Aug 201911:45 amRNSResult of General Meeting and Open Offer
8th Aug 20197:00 amRNSPlacing, Open Offer and Notice of General Meeting
31st Jul 20197:00 amRNSHalf-year Report
25th Jul 20197:00 amRNSCollaboration with National Imaging Academy Wales
10th Jul 20197:00 amRNSTrading update
4th Jul 20197:46 amRNSFirst OEM agreement for AI based imaging software
23rd May 20193:14 pmRNSResult of AGM
23rd May 20197:00 amRNSAGM Statement
16th May 20197:00 amRNSFirst live demonstration of ScanNav AnatomyGuide
30th Apr 20197:00 amRNSNotice of Annual General Meeting
28th Mar 20197:00 amRNSFinal Results
19th Feb 20197:00 amRNSNotice of Results
24th Jan 20197:00 amRNSInvestor presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.